Last edition
News about "Jonathan Sporn"
AbbVie to Acquire Gilgamesh's Psychedelic Antidepressant Bretisilocin in USD 1.2 Billion Deal
AbbVie has announced a USD 1.2 billion deal to acquire Gilgamesh Pharmaceuticals’ lead candidate bretisilocin, a next-generation psychedelic compound in clinical development for treating moderate-to-severe major depressive disorder.
Jonathan Sporn | 26/08/2025 | By Mrinmoy Dey
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members